Controlled release systems of angiogenic growth factors for cardiovascular diseases

• URBICH C, DIMMELER S: Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. (2004) 95(4):343-353.
   PubMed Web of Science ®Google Scholar
• CARMELIET P: Mechanisms of angiogenesis and arteriogenesis. Nat. Med. (2000) 6(4):389-395.
   PubMed Web of Science ®Google Scholar
• WAHLBERG E: Angiogenesis and arteriogenesis in limb ischemia. J. Vasc. Surg. (2003) 38(1):198-203.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER H-P, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, KAWAMOTO A: Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol. Cell Physiol. (2004) 287(3):C572-C579.
   PubMed Web of Science ®Google Scholar
• ORNITZ D, ITOH N: Fibroblast growth factors. Genome Biol. (2001) 2(3):ReviewS3005.
   PubMedGoogle Scholar
• FUNAKOSHI H, NAKAMURA T: Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta (2003) 327(1-2):1-23.
   PubMed Web of Science ®Google Scholar
• LAHAM RJ, REZAEE M, POST M et al.: Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab. Dispos. (1999) 27(7):821-826.
   PubMed Web of Science ®Google Scholar
• BAUMGARTNER I, PIECZEK A, MANOR O et al.: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 97(12):1114-1123.
   PubMed Web of Science ®Google Scholar
• UNGER EF, GONCALVES L, EPSTEIN SE et al.: Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am. J. Cardiol. (2000) 85(12):1414-1419.
   PubMed Web of Science ®Google Scholar
• ESKENS FALM, VERWEJ J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur. J. Cancer (2006) 42(18):3127-3139.
   PubMed Web of Science ®Google Scholar
• POWERS CJ, MCLESKEY SW, WELLSTEIN A: Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer (2000) 7(3):165-197.
   PubMed Web of Science ®Google Scholar
• PETER AC: Molecular targets for retinal vascular diseases. J. Cell Physiol. (2007) 210(3):575-581.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Molecular regulation of vessel maturation. Nat. Med. (2003) 9(6):685-693.
   PubMed Web of Science ®Google Scholar
• GILGENKRANTZ H, DUBOC D, JUILLARD V et al.: Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum. Gene Ther. (1995) 6:1265-1274.
   PubMed Web of Science ®Google Scholar
• GRUCHALA M, BHARDWAJ S, PAJUSOLA K et al.: Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J. Gene Med. (2004) 6(5):545-554.
   PubMed Web of Science ®Google Scholar
• MARSHALL E; CLINICAL TRIALS: Gene therapy death prompts review of adenovirus vector. Science (1999) 286(5448):2244-2245.
   PubMed Web of Science ®Google Scholar
• SIMONS M, ANNEX BH, LAHAM RJ et al.: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation (2002) 105(7):788-793.
   PubMed Web of Science ®Google Scholar
• LAHAM RJ, REZAEE M, POST M et al.: Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab. Dispos. (1999) 27(7):821-826.
   PubMed Web of Science ®Google Scholar
• HENRY TD, ANNEX BH, MCKENDALL GR et al.: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation (2003) 107(10):1359-1365.
   PubMed Web of Science ®Google Scholar
• GRINES CL, WATKINS MW, HELMER G et al.: Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation (2002) 105(11):1291-1297.
   PubMed Web of Science ®Google Scholar
• GRINES CL, WATKINS MW, MAHMARIAN JJ et al.: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. (2003) 42(8):1339-1347.
   PubMed Web of Science ®Google Scholar
• BARBEAU G, BEATT K, BETRIU A et al.: Adenoviral fibroblast growth factor-4 gene therapy in patients with stable angina. 12-month results of a double blind randomized multicenter trial. J. Am. Coll. Cardiol. (2006) 47(Suppl. 1):A305.
   Google Scholar
• HENRY TD, GRINES CL, WATKINS MW et al.: Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. (2007) 50(11):1038-1046.
   PubMed Web of Science ®Google Scholar
• HEDMAN M, HARTIKAINEN J, SYVANNE M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio angiogenesis trial (KAT). Circulation (2003) 107(21):2677-2683.
   PubMed Web of Science ®Google Scholar
• KASTRUP J, JORGENSEN E, RUCK A et al.: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject one trial. J. Am. Coll. Cardiol. (2005) 45(7):982-988.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, HILTON JD, ARNOLD JMO et al.: Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a Phase II randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. (2006) 13(21):1503-1511.
   PubMed Web of Science ®Google Scholar
• RIPA RS, WANG Y, JORGENSEN E, JOHNSEN HE, HESSE B, KASTRUP J: Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. (2006) 27(15):1785-1792.
   PubMed Web of Science ®Google Scholar
• LEDERMAN RJ, MENDELSOHN FO, ANDERSON RD et al.: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet (2002) 359(9323):2053-2058.
   PubMed Web of Science ®Google Scholar
• MAKINEN K, MANNINEN H, HEDMAN M et al.: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol. Ther. (2002) 6(1):127-133.
   PubMed Web of Science ®Google Scholar
• KUSUMANTO YH, VAN WEEL V, MULDER NH et al.: Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. (2006) 17(6):683-691.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, MOHLER ER III, LEDERMAN RJ et al.: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation (2003) 108(16):1933-1938.
   PubMed Web of Science ®Google Scholar
• POWELL RJ, DORMANDY J, SIMONS M, MORISHITA R, ANNEX BH: Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc. Med. (2004) 9(3):193-198.
   PubMed Web of Science ®Google Scholar
• TABATA Y, IKADA Y: Protein release from gelatin matrices. Adv. Drug Deliv. Rev. (1998) 31(3):287-301.
   PubMed Web of Science ®Google Scholar
• TABATA Y: Tissue regeneration based on growth factor release. Tissue Eng. (2003) 9(Suppl. 1):S5-S15.
   PubMedGoogle Scholar
• EDELMAN ER, MATHIOWITZ E, LANGER R, KLAGSBRUN M: Controlled and modulated release of basic fibroblast growth factor. Biomaterials (1991) 12(7):619-626.
   PubMed Web of Science ®Google Scholar
• LAHAM RJ, SELLKE FW, EDELMAN ER et al.: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a Phase I randomized, double-blind, placebo-controlled trial. Circulation (1999) 100(18):1865-1871.
   PubMed Web of Science ®Google Scholar
• SAKAKIBARA Y, TAMBARA K, SAKAGUCHI G et al.: Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur. J. Cardiothorac. Surg. (2003) 24(1):105-111; discussion 12.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY L: Surgical treatment of cardiac ischemia. Lancet (1937) 232:185-194.
   Google Scholar
• UEYAMA K, BING G, TABATA Y et al.: Development of biologic coronary artery bypass grafting in a rabbit model: revival of a classic concept with modern biotechnology. J. Thorac. Cardiovasc. Surg. (2004) 127(6):1608-1615.
   PubMed Web of Science ®Google Scholar
• TAKABA K, JIANG C, NEMOTO S et al.: A combination of omental flap and growth factor therapy induces arteriogenesis and increases myocardial perfusion in chronic myocardial ischemia: evolving concept of biologic coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. (2006) 132(4):891-899.
   PubMed Web of Science ®Google Scholar
• SAKAKIBARA Y, NISHIMURA K, TAMBARA K et al.: Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J. Thorac. Cardiovasc. Surg. (2002) 124(1):50-56.
   PubMed Web of Science ®Google Scholar
• TAMBARA K, PREMARATNE GU, SAKAGUCHI G et al.: Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation (2005) 112(9 Suppl.):I129-I134.
   PubMed Web of Science ®Google Scholar
• DOI K, IKEDA T, MARUI A et al.: Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels (2007) 22(2):104-108.
   PubMed Web of Science ®Google Scholar
• MARUI A, KANEMATSU A, YAMAHARA K et al.: Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J. Vasc. Surg. (2005) 41(1):82-90.
   PubMed Web of Science ®Google Scholar
• HIROSE K, FUJITA M, MARUI A et al.: Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. Circ. J. (2006) 70(9):1190-1194.
   PubMed Web of Science ®Google Scholar
• MARUI A, TABATA Y, KOJIMA S et al.: A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the Phase I – IIa study. Circ. J. (2007) 71(8):1181-1186.
   PubMed Web of Science ®Google Scholar
• RIVARD A, FABRE J-E, SILVER M et al.: Age-dependent impairment of angiogenesis. Circulation (1999) 99(1):111-120.
   PubMed Web of Science ®Google Scholar
• VAN BELLE E, RIVARD A, CHEN D et al.: Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation (1997) 96(8):2667-2674.
   PubMedGoogle Scholar

Websites

• http://clinicaltrials.gov/ct/ show/NCT00438867 ClinicalTrials.gov. Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization (AWARE). Accessed 22nd September 2007.
   Google Scholar
• http://clinicaltrials.gov/ct/ show/NCT00143585 ClinicalTrials.gov. NOGA angiogenesis revascularization therapy: evaluation by radionuclide imaging – the Northern Trial. Accessed 22nd September 2007.
   Google Scholar
• http://clinicaltrials.gov/ct/ show/NCT00215696 ClinicalTrials.gov. A study to treat patients whose chronic angina symptoms are not relieved by medication and have an area of the heart that cannot be treated by standard therapies. Accessed 22nd September 2007.
   Google Scholar
• http://www.medicalnewstoday.com/articles/44335.php Medical News Today: Corautus Genetics announces filing of response to FDA Clinical Hold. Accessed 22nd September 2007.
   Google Scholar
• http://www.medicalnewstoday.com/articles/53786.php Medical News Today: Corautus Genetics announces final efficacy results of GENASIS Phase IIb Clinical Trial. Accessed 22nd September 2007.
   Google Scholar
• http://www.medscape.com/viewarticle/528474 Medscape Today TALISMAN 201: Therapeutic Angiogenesis Leg Ischemia Study for the management of arteriopathy and non-Healing ulcer. Accessed 22nd September 2007.
   Google Scholar
• http://www.anges-mg.com/en/news/060605_1.htm AnGes MG, Inc. releases the results of the US Phase II Clinical Trial with HGF gene plasmid for PAD (Peripheral arterial disease). Accessed 22nd September 2007.
   Google Scholar